多体学市场规模、份额和成长分析（按产品/服务、类型、平台、应用、最终用户和地区划分）—2026-2033年产业预测

预计到 2024 年，全球多体学市场规模将达到 36.1 亿美元，到 2025 年将达到 42 亿美元，到 2033 年将达到 141.5 亿美元，在预测期（2026-2033 年）内，复合年增长率为 16.4%。

全球多体学领域正经历显着增长，这主要得益于人们对个人化医疗日益增长的兴趣、基因组学和蛋白​​质组学领域的大量投资，以及多组体学在药物研发和临床诊断中应用范围的不断扩大。定序技术和数据分析的进步推动了这一成长，而医疗保健格局在製药和研究领域也在不断演变。慢性病发病率的上升以及生物医学研究领域大量的公共和私人资金投入，都推动了对多体学的需求。製药公司正越来越多地采用多体学技术来简化药物研发流程并识别新的治疗标靶。然而，高昂的研发成本、熟练专家的短缺、数据整合问题以及标准化程度有限等挑战，可能会阻碍其未来的市场渗透。

全球多体学市场驱动因素

全球多体学市场受到个人化医疗需求日益增长的显着影响，而基因组学、蛋白质组学和代谢体学等技术的应用正是推动个人化治疗方法发展的关键因素。这些先进工具使医疗专业人员能够根据个人独特的基因和生物学特征制定个人化治疗方案。因此，医院、製药公司和研究机构正越来越多地采用多体学方法来增强药物标靶化和提高诊断准确性。社会对更有效、更快速的治疗方法的需求不断增长，进一步强化了对个人化、数据驱动型医疗解决方案的关注。因此，多组体学正逐渐成为现代医疗实践的重要组成部分。

限制全球多组体学市场的因素

全球多体学市场面临许多限制因素，主要源自于建立和维护多组体学实验室的高昂成本。必要的配套基础设施，包括先进设备、专用软体和充足的数据存储，价格可能极其昂贵，尤其是在发展中地区，这些工具难以取得。此外，儘管市场对能够有效管理和解读多体学研究产生的复杂数据的专业人员需求旺盛，但合格的专业人员却严重短缺。这些经济负担，加上人员短缺的挑战，阻碍了多组体学在资源匮乏地区的发展和扩张。

全球多体学市场趋势

将多体学技术整合到临床应用和精准医疗中，是全球多组体学市场的一大显着趋势。该领域的企业正优先开发针对癌症、心血管疾病和神经系统疾病的专用诊断工具，以促进早期发现并加强治疗监测。随着对个人化医疗解决方案的需求日益增长，多组体学在临床实践中的应用正为患者管理的创新方法铺平道路。这项发展不仅使市场参与者在竞争格局中脱颖而出，也为精准医疗的成长和进步创造了广阔的机会，最终将改善患者预后并提高医疗效率。

目录

介绍

• 调查目标
• 市场定义和范围

调查方法

• 调查过程
• 二手资料和一手资料方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争格局概述

市场动态与展望

• 总体经济指标
• 驱动因素和机会
• 限制与挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

关键市场考察

• 关键成功因素
• 影响市场的因素
• 关键投资机会
• 生态系测绘
• 市场吸引力指数（2025）
• PESTEL 分析
• 价值链分析
• 定价分析
• 案例研究
• 监管环境
• 技术评估

全球多元体学市场规模（依产品及服务划分）及复合年增长率（2026-2033 年）

• 产品
  • 装置
  • 消耗品
  • 软体
• 服务

全球多体学市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 单细胞多组体学
• 批量体学

全球多体学市场规模（按平台和复合年增长率划分）（2026-2033 年）

• 基因组学
• 转录组学
• 蛋白质体学
• 代谢体学
• 整合组体学平台

全球多体学市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 诊断
• 药物发现与开发
• 个人化医疗
• 农业基因组学
• 其他的

全球多体学市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 製药和生物技术公司
• 学术研究机构
• 临床研究机构（CRO）
• 其他的

全球多组体学市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Thermo Fisher Scientific Inc.（United States）
• Illumina, Inc.（United States）
• Danaher Corporation（United States）
• QIAGEN NV（Germany）
• Agilent Technologies, Inc.（United States）
• PerkinElmer, Inc.（United States）
• Bruker Corporation（United States）
• Becton, Dickinson and Company（BD）（United States）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• 10x Genomics, Inc.（United States）
• Shimadzu Corporation（Japan）
• BGI Genomics（China）
• Bio-Rad Laboratories, Inc.（United States）
• Mission Bio, Inc.（United States）
• Standard BioTools（United States）
• NanoString Technologies（United States）
• CYTENA GmbH（Germany）
• Tempus Labs, Inc.（United States）
• DNAnexus, Inc.（United States）
• Eurofins Scientific SE（Luxembourg）

结论与建议

Global Multiomics Market size was valued at USD 3.61 Billion in 2024 and is poised to grow from USD 4.2 Billion in 2025 to USD 14.15 Billion by 2033, growing at a CAGR of 16.4% during the forecast period (2026-2033).

The global multiomics sector is experiencing significant growth driven by heightened interest in personalized medicine, robust investments in genomics and proteomics, and an increasing application of multiomics for drug discovery and clinical diagnostics. Technological advancements in sequencing and data analysis are facilitating this expansion, while the healthcare landscape continues to evolve within pharmaceutical and research domains. The demand for multiomics is being propelled by the rising prevalence of chronic diseases and substantial public and private funding in biomedical research. Pharmaceutical firms are adopting multiomics technologies to streamline drug discovery and identify new therapeutic targets. Nonetheless, challenges such as high research costs, a shortage of skilled professionals, data integration issues, and limited standardization may impede further market penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiomics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiomics Market Segments Analysis

Global Multiomics Market is segmented by Products and Services, Type, Platform, Application, End User and region. Based on Products and Services, the market is segmented into Products and Services. Based on Type, the market is segmented into Single-cell Multiomics and Bulk Multiomics. Based on Platform, the market is segmented into Genomics, Transcriptomics, Proteomics, Metabolomics and Integrated Omics Platforms. Based on Application, the market is segmented into Diagnostics, Drug Discovery and Development, Personalized Medicine, AgriGenomics and Others. Based on End User, the market is segmented into Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Clinical Research Organizations (CROs) and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiomics Market

The global multiomics market is significantly influenced by the rising demand for personalized medicine, which leverages technologies like genomics, proteomics, and metabolomics. These advanced tools empower healthcare professionals to develop tailored treatments that cater to individuals' unique genetic and biological profiles. As a result, hospitals, pharmaceutical companies, and research laboratories are increasingly adopting multiomics approaches to enhance drug targeting and improve diagnostic accuracy. With a growing public desire for more effective and expedited treatment options, the focus on personalized, data-driven healthcare solutions intensifies. Consequently, multiomics is emerging as an essential component in modern healthcare practices.

Restraints in the Global Multiomics Market

The Global Multiomics market faces significant constraints primarily due to the high costs associated with setting up and maintaining multiomics laboratories. The necessary infrastructure, including advanced instruments, specialized software, and ample data storage, can be prohibitively expensive, especially in developing regions where facilities often struggle to acquire these tools. Additionally, there is a considerable demand for skilled personnel who can effectively manage and interpret the intricate data generated by multiomics studies, yet there is a notable shortage of such qualified professionals. This combination of financial burdens and staffing challenges hinders the growth and expansion of multiomics in resource-constrained environments.

Market Trends of the Global Multiomics Market

The Global Multiomics market is witnessing a significant trend towards the integration of multiomics technologies in clinical applications and precision medicine. Companies in this sector are prioritizing the development of diagnostic tools tailored to oncology, cardiovascular, and neurological disorders, which facilitate early detection and enhance treatment monitoring. As the demand for personalized healthcare solutions grows, the translation of multiomics into clinical practice paves the way for innovative approaches to patient management. This evolution not only distinguishes market players in a competitive landscape but also opens up expansive opportunities for growth and advancement in precision medicine, ultimately improving patient outcomes and healthcare efficiency.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Multiomics Market Size by Products and Services & CAGR (2026-2033)

• Market Overview
• Products
  • Instruments
  • Consumables
  • Software
• Services

Global Multiomics Market Size by Type & CAGR (2026-2033)

• Market Overview
• Single-cell Multiomics
• Bulk Multiomics

Global Multiomics Market Size by Platform & CAGR (2026-2033)

• Market Overview
• Genomics
• Transcriptomics
• Proteomics
• Metabolomics
• Integrated Omics Platforms

Global Multiomics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Diagnostics
• Drug Discovery and Development
• Personalized Medicine
• AgriGenomics
• Others

Global Multiomics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Clinical Research Organizations (CROs)
• Others

Global Multiomics Market Size & CAGR (2026-2033)

• North America (Products and Services, Type, Platform, Application, End User)
  • US
  • Canada
• Europe (Products and Services, Type, Platform, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Products and Services, Type, Platform, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Products and Services, Type, Platform, Application, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Products and Services, Type, Platform, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bruker Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 10x Genomics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shimadzu Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BGI Genomics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mission Bio, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Standard BioTools (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoString Technologies (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CYTENA GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tempus Labs, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DNAnexus, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific S.E. (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations